Personalized CRISPR cures CPS1 baby
- Children’s Hospital of Philadelphia and Penn Medicine said baby KJ became the first patient ever treated with a bespoke CRISPR therapy for severe CPS1 deficiency. (nih.gov) - The team went from diagnosis to treatment in 6 months, gave three doses by April 2025, and said KJ was growing well without serious side effects. (nih.gov) - It matters because most rare mutations are too small a market for standard drug development, so this case hints at an “N-of-1” gene-editing model. (chop.edu)
A customized CRISPR drug just did something medicine has wanted to do for years — fix the exact mutation in one exact patient, fast enough to matter. The patient was a baby a(nih.gov)hey’re old enough for a liver transplant. The news is that CHOP and Penn Medicine built a one-off gene-editing treatment for him, delivered the first dose in February 2025, and said he was doing well after three doses with no serious side effects. (nih.gov) ### What is CPS1 deficiency? CPS1 deficiency is (chop.edu)PS1 enzyme is broken, ammonia builds up instead. In newborns, that can mean brain injury, coma, liver damage, or death very quickly. Standard care is a brutally restrictive diet, ammonia-lowering drugs, and usually a liver transplant if the child survives long enough. About half of infants with the condition die in early infancy. (nih.gov) ### Why wasn’t a normal CRISPR drug enough? Because this baby’s mutation was his own. Most gene-ed(nih.gov)le. Rare-disease medicine breaks that model. There are thousands of mutations, many seen in only a handful of people — or one. So the team had to make a therapy tailored to KJ’s exact DNA error rather than pull something off a shelf. (chop.edu) ### What did they actually build? They used CRISPR base editing, not the older cut-and-paste version people usually picture. That matters because (nih.gov) at KJ’s specific CPS1 mutation, all wrapped in lipid nanoparticles and infused into the liver, where CPS1 normally does its job. (nih.gov) ### Why did speed matter so much? Because this was a race against infant metabolism. The team said the path from diagnosis to first treatment took 6 months, which is incredibly fast for a bespoke therapy. KJ got his first dose when he (chop.edu) infection, dehydration episode, or feeding problem can trigger a crisis. (nih.gov) ### Did it work? Early signs say yes — with important caveats. By April 2025, KJ had received three doses. The team said he tolerated them without serious adverse events, was growing well, and could eat(nih.gov) nobody should confuse “promising rescue” with “fully proven cure” yet. (pennmedicine.org) ### Why is this bigger than one baby? Because it suggests a manufacturing template. The reusable parts — delivery system, editing platform, testing workflow — can stay mostly the same while the guide gets swapped for a new mutation. That is the rea(nih.gov)ng process for ultra-rare disease. (nih.gov) ### What’s the catch? Everything around the science. One-patient therapies are hard to regulate, hard to manufacture, and hard to pay for. The biology may be customizable, but the health-care system is stil(pennmedicine.org)t thousands of families can get the same thing next year. (chop.edu) ### Bottom line The breakthrough is not just that CRISPR helped one baby. It’s that doctors built a mutation-specific treatment in time to change the course of a lethal infant disease. That turns personalized gene editing from a cool idea into a real clinical model — but now medicine has to figure out how to make that model routine. (nih.gov)
